Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx ingredients found in U.K. herbal

This article was originally published in The Tan Sheet

Executive Summary

The Medicines and Healthcare products Regulatory Agency seizes a traditional Chinese medicinal product sold in the U.K., Jia Yi Jian, after the product tested positive for high levels of prescription-only ingredients. The agency said April 7 that the adulterated product "presents a clear risk to consumers" by using natural ingredient claims to distract from what are likely "very low manufacturing and ethical standards." Lab testing showed Jia Yi Jian, manufactured by Hu Nan Aimin Pharmaceuticals, contains more than twice the legal dosage of the erectile dysfunction drug tadalafil, the active ingredient in Lilly's prescription Cialis, and more than four times the legal dosage of the obesity drug sibutramine, the active ingredient in Abbott's prescription Meridia

You may also be interested in...



EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty

Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.

Emerging Markets Help Fresenius Kabi Offset US Pressures

Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.

Fresenius Kabi And Vifor Ally In China

Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.

Topics

UsernamePublicRestriction

Register

PS102810

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel